Unum Therapeutics (NASDAQ:UMRX) had its price objective reduced by Wedbush from $20.00 to $13.00 in a research report released on Tuesday morning, The Fly reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for Unum Therapeutics’ Q3 2019 earnings at ($0.30) EPS, Q4 2019 earnings at ($0.23) EPS, FY2019 earnings at ($1.27) EPS, FY2020 earnings at ($0.83) EPS, FY2021 earnings at ($1.39) EPS, FY2022 earnings at ($1.17) EPS and FY2023 earnings at $0.04 EPS. The analysts noted that the move was a valuation call.
Several other equities analysts have also weighed in on the company. HC Wainwright restated a buy rating on shares of Unum Therapeutics in a research note on Tuesday. Zacks Investment Research upgraded Unum Therapeutics from a hold rating to a buy rating and set a $4.00 price target for the company in a research note on Friday, April 26th. SunTrust Banks cut their price target on Unum Therapeutics to $6.00 and set a buy rating for the company in a research note on Wednesday, July 3rd. Finally, ValuEngine upgraded Unum Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $12.40.
NASDAQ UMRX opened at $2.00 on Tuesday. The stock has a 50-day simple moving average of $2.22 and a two-hundred day simple moving average of $3.34. The firm has a market capitalization of $58.56 million, a P/E ratio of -1.44 and a beta of 1.38. Unum Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $16.72. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.65 and a current ratio of 2.41.
Several institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP purchased a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $62,000. Jane Street Group LLC purchased a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $132,000. Paloma Partners Management Co purchased a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $227,000. Acadian Asset Management LLC increased its stake in shares of Unum Therapeutics by 134.8% in the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock valued at $85,000 after purchasing an additional 18,717 shares in the last quarter. Finally, Wasatch Advisors Inc. increased its stake in shares of Unum Therapeutics by 64.5% in the 1st quarter. Wasatch Advisors Inc. now owns 254,449 shares of the company’s stock valued at $1,117,000 after purchasing an additional 99,814 shares in the last quarter. Hedge funds and other institutional investors own 47.16% of the company’s stock.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Featured Story: What is the Rule of 72?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.